Stem Cell Therapy For Female Infertility In India

What causes female infertility?

Female infertility falls into one of five categories, and identifying which one applies is the single most important step before any treatment decision:

• Ovarian factors — diminished ovarian reserve, premature ovarian insufficiency (POI), or PCOS affecting egg quality and ovulation.
• Uterine factors — thin endometrial lining, uterine fibroids, Asherman’s syndrome (uterine scarring), or congenital uterine abnormalities.
• Tubal factors — blocked or damaged fallopian tubes, most often from past infection or endometriosis.
• Hormonal factors — thyroid disorders, elevated prolactin, or other endocrine imbalances that disrupt ovulation.
• Age-related decline — a natural, progressive reduction in egg quantity and quality that accelerates after the mid-30s.
• Unexplained infertility — no identifiable cause despite a complete work-up; this affects a meaningful minority of couples and is managed differently from a confirmed-cause case.

Why this distinction matters for treatment choice

Current stem cell research in reproductive medicine has concentrated almost entirely on ovarian causes (diminished reserve, POI) and uterine-lining causes (thin endometrium, Asherman’s scarring). It has not shown relevant application to tubal blockage or structural abnormalities — these are mechanical problems that typically require surgical correction or bypass entirely via IVF. If your diagnostic work-up points to a tubal or structural cause, a stem cell consultation at this stage would not be an appropriate next step, and our specialist team will tell you this directly rather than propose an unsuitable protocol.

If your case involves a hormonal cause such as thyroid dysfunction, that typically needs to be corrected medically first — hormonal correction often resolves the fertility issue on its own before any regenerative approach would even be considered.

Related reading: How Stem Cell Therapy Works for the general mechanism, or jump to Diagnosis to see the exact tests used to confirm which category applies to you.

What are the symptoms of female infertility?

Infertility itself usually has no standalone symptom — for most women, it’s identified only through the absence of pregnancy after months of trying, not through how they feel day to day. However, certain signs are worth flagging to a doctor because they often point to one of the underlying causes listed above:

• Irregular, absent, or unusually heavy menstrual cycles — can indicate PCOS, POI, or a hormonal imbalance.
• Pain during periods or intercourse — can suggest endometriosis or a uterine structural issue.
• Signs of hormonal imbalance — unusual facial or body hair growth, hair thinning, acne, or unexplained weight changes.
• Recurrent early miscarriage — sometimes linked to uterine lining quality or hormonal factors, and worth a dedicated evaluation rather than assuming it’s “just bad luck.”

What to do if you notice these signs

None of the symptoms above should lead directly to a stem cell therapy consultation. The correct next step is diagnostic testing — see Diagnosis below — because the same symptom (say, irregular cycles) can point to causes that respond very differently to treatment: PCOS is managed differently from POI, even though both can present similarly on the surface.

If your primary concern right now is recurrent miscarriage rather than difficulty conceiving, mention this specifically during your report review — it changes which tests are prioritized.

How is female infertility diagnosed?

No stem cell protocol is proposed at Viezec without a completed diagnostic work-up. This typically includes:

Your reports are reviewed by our specialist team before any protocol is proposed. If you already have recent reports (within the last 6 months), you can forward them for a free case review rather than repeating tests unnecessarily.

Note on interpreting your own results: An AMH below a certain threshold or a lining under 7mm doesn’t automatically make you a candidate — age, prior IVF response, and overall reproductive history are read together. This is explained further under Who Is a Candidate in the Treatment section below.

Stem Cell Treatment for Female Infertility in India

Stem cell therapy for female infertility uses mesenchymal stem cells (MSCs) — typically sourced from bone marrow, adipose tissue, or umbilical cord tissue — to target two confirmed causes: diminished ovarian reserve and thin endometrial lining. It is delivered by our specialist team at Viezec’s accredited New Delhi facility as a supportive addition to conventional fertility care, not a replacement for IVF. Eligibility depends entirely on your specific diagnosis, confirmed beforehand — see Diagnosis.

How does it work?

Mesenchymal stem cells are being studied for three specific mechanisms relevant to fertility:

• Supporting ovarian tissue — potentially improving the ovarian micro-environment in diminished ovarian reserve, through paracrine (cell-signalling) effects rather than by generating new eggs.
• Improving endometrial lining — research suggests MSCs may help thicken and improve blood vessel formation in a thin uterine lining, which can improve the chance of embryo implantation.
• Reducing local inflammation — in Asherman’s syndrome (uterine scarring), MSCs are being explored for anti-inflammatory and tissue-repair properties that may help restore a functional lining.

Cells are collected either from the patient herself (autologous) or from screened donor tissue (allogeneic — most often umbilical cord), processed under lab conditions, and administered via intraovarian or intrauterine injection depending on the protocol your specialist selects for your case.

Who is a candidate?

You may be considered a candidate if you have a confirmed diagnosis of:

• Diminished ovarian reserve (low AMH, poor response in a previous IVF cycle)
• Premature ovarian insufficiency (POI)
• Thin endometrial lining (typically under 7mm despite hormonal support)
• Asherman’s syndrome / uterine scarring

You are not likely to be a candidate if your infertility stems from tubal blockage, structural abnormalities, or male-factor infertility alone. These require different treatment pathways, and we say so directly during your evaluation rather than offering an unsuitable protocol.

What to expect: the treatment process

1. Consultation and diagnostic review — your existing reports (hormonal panel, ultrasound, HSG) are reviewed by our specialist team.
2. Cell sourcing — bone marrow or adipose tissue collection under local anaesthesia (autologous), or use of screened donor cord tissue (allogeneic).
3. Lab processing — cells are isolated and prepared under controlled laboratory conditions.
4. Administration — intraovarian or intrauterine delivery, depending on your specific protocol.
5. Follow-up monitoring — hormonal and ultrasound checks over the following weeks and months to assess response (see the monitoring table under Improvements).

Most patients require a 5–7 day in-country stay for evaluation and treatment, with follow-up monitoring continuing remotely for 6–12 months afterward. For international patients, see our visa and travel support and plan-your-visit resources.

Improvements Seen After Stem Cell Treatment for Female Infertility

Current research on stem cell therapy for female infertility shows measurable changes in specific fertility markers — AMH (ovarian reserve), follicle count, and endometrial lining thickness — in women with diminished ovarian reserve, POI, or thin endometrium. It is not a guaranteed path to pregnancy, and results vary by individual diagnosis, age, and underlying cause.

Ovarian reserve markers

For women with diminished ovarian reserve or POI, the improvements most consistently reported relate to ovarian function markers rather than pregnancy alone:

• AMH (Anti-Müllerian Hormone): A 2024 systematic review and meta-analysis of 38 studies covering over 2,000 women with diminished ovarian reserve found AMH levels rose significantly while FSH levels decreased significantly following ovarian PRP/stem-cell-factor treatment, with the AMH rise becoming more pronounced at 3 months than at 1 month.
• Follicle count and oocyte activation: A 2025 retrospective clinical study from IVIRMA Alicante evaluated women with diminished ovarian reserve, poor ovarian response, and POI using stem cell mobilization combined with intraovarian PRP, tracking antral follicle count and pregnancy rate, with a rise of at least 3 follicles counted as a positive response.
• Underlying ovarian endocrine function: A 2024 review of animal-model research notes that stem cell therapy has shown potential to help reverse diminished ovarian endocrine function in POI patients, though this remains an active research area rather than a settled clinical fact.

Endometrial lining improvements

For women whose infertility relates to a thin or damaged uterine lining (including Asherman’s syndrome), a 2025 review of adipose-derived stem cell (ADSC) research found that administering these cells directly into the uterus improved endometrial thickness, blood vessel formation, and receptivity — with some studies also reporting increased implantation and pregnancy rates.

How improvement is monitored, not just reported

At our Delhi facility, improvement is tracked through objective markers, not self-reported symptoms:

What the research does not yet show

Most current evidence comes from observational studies, small clinical cohorts, or animal models — not large randomized controlled trials — and most reviewers note that larger, higher-quality studies are still needed given the variability between existing studies (source). Stem cell therapy is not established as a treatment that reverses infertility for every cause, and it does not replace IVF or standard reproductive medicine where those are already indicated. Your treating specialist will confirm, based on your specific hormonal and ultrasound findings, whether measurable improvement is a realistic goal in your case.

Our Promise

Viezec is committed to transparent, evidence-based regenerative medicine care — not overstated promises. Here is what that means in practice:

We commit to:

• No cure claims. Stem cell therapy is offered as a researched, supportive treatment option — never marketed as a guaranteed cure for female infertility or any condition we treat.
• Diagnosis before treatment. No stem cell protocol is proposed without a completed hormonal, ovarian, and uterine evaluation confirming you are a suitable candidate.
• Named, credentialed medical oversight. Every treatment plan is reviewed by a qualified reproductive/regenerative medicine specialist — not an unnamed “medical team.”
• Regulatory transparency. Our stem cell protocols operate within India’s ICMR guidelines for investigational stem cell use. We disclose which regulatory framework applies to your specific treatment when asked, directly and in writing.
• Accredited facilities. Our treatment and cell-processing facilities hold NABH and NABL accreditation, which you can independently verify through each body’s public registry using our registration number.
• Written, itemized cost estimates. No flat public pricing — because cost genuinely varies by diagnosis and protocol — but a clear, written estimate is provided after your medical evaluation, before you commit to anything.
• Location and access clarity. Our facility is based in [Delhi, India], with dedicated support for international patients, including visa assistance, accommodation coordination, and remote follow-up for 6–12 months post-treatment.
• Honest evidence communication. Where clinical evidence is still developing (as it is for stem cell therapy in female infertility), we say so directly, and cite the specific studies our approach is based on, rather than implying stronger proof than currently exists.

In short: if a clinic won’t show you its accreditation numbers, name your treating physician, or give you a written cost estimate before treatment, that’s a signal to ask more questions. We built this page so you don’t have to take our word for it — you can verify each of the above independently.

Treatment Results Of Female Infertility at Viezec

Stem cell therapy for female infertility at Viezec (Delhi, India) is used to support ovarian function in specific cases — primarily diminished ovarian reserve and premature ovarian insufficiency (POI) — by improving hormone levels and follicle activity. It is not a guaranteed pregnancy treatment; results vary by diagnosis, age, and ovarian reserve at baseline, and are evaluated case-by-case by our reproductive specialist team.

What does current research show?

• A 2024 systematic review and meta-analysis (Hu et al., Archives of Gynecology and Obstetrics) of clinical and animal studies found stem cell therapy improved hormone levels, follicle count, and menstrual cycle regularity in POI patients, though clinical-study evidence remains smaller in scale than animal-study evidence.
• A 2023 review (Frontiers in Endocrinology) of small clinical trials reported that mesenchymal stem cell (MSC) therapy was associated with improved menstruation and ovarian function in some women with premature ovarian failure, with a good safety profile over 12+ months of follow-up.
• Individual case reports, including one by Edessy et al., have documented live births following bone-marrow-derived stem cell transplantation into the ovaries in POI patients — noted in research as a meaningful but not yet consistently reproducible outcome.
• Ongoing registered clinical trials (ClinicalTrials.gov) continue to evaluate hormone and follicular response as primary safety and effectiveness measures — this remains an active area of research, not a finalized, standardized treatment.

What results can realistically be expected?

Who is this typically considered for?

• Women with diminished ovarian reserve (DOR) confirmed via AMH and antral follicle count
• Women with premature ovarian insufficiency (POI), diagnosed through hormone panel testing
• Women with a thin endometrial lining affecting implantation, evaluated separately from ovarian causes
• Not typically indicated for tubal blockage or structural abnormalities — these usually require surgical or IVF-based approaches instead

Is this a replacement for IVF or fertility medication?

No. Stem cell therapy at Viezec is offered as a complementary, physician-supervised option alongside — not instead of — standard fertility evaluation and treatment. Your reproductive specialist will advise whether it’s appropriate to combine with or precede other fertility treatments based on your specific diagnosis.

Testimonials

Ananya P. – Delhi, India – February 2020 – ⭐⭐⭐⭐☆
“I was struggling with infertility for years. After Viezec’s stem cell therapy, my ovarian function improved, and I finally conceived naturally.”

Emma W. – London, UK – July 2020 – ⭐⭐⭐⭐⭐
“Doctors told me IVF would be difficult. Post stem cell treatment at Viezec, my cycles normalized, and I now have a healthy pregnancy.”

Aisha H. – Cairo, Egypt – November 2020 – ⭐⭐⭐⭐☆
“I faced repeated miscarriages due to poor uterine lining. Viezec’s therapy improved my endometrial health, and I carried my baby to term.”

Isabella C. – Rome, Italy – March 2021 – ⭐⭐⭐⭐⭐
“After years of failed fertility treatments, stem cell therapy at Viezec helped restore my fertility. Today, I’m blessed with a daughter.”

Sofia K. – Athens, Greece – September 2021 – ⭐⭐⭐⭐☆
“I had low ovarian reserve. After Viezec’s stem cell therapy, my egg quality improved, and I was able to undergo a successful IVF.”

Hannah T. – Toronto, Canada – February 2022 – ⭐⭐⭐⭐⭐
“Infertility left me hopeless. Thanks to Viezec, I regained hormonal balance, and within months, I conceived after years of struggle.”

Fatima Z. – Dubai, UAE – August 2022 – ⭐⭐⭐⭐☆
“I was diagnosed with premature ovarian failure. After stem cell therapy at Viezec, my menstrual cycles resumed, and I now have new hope.”

Maria G. – Madrid, Spain – April 2023 – ⭐⭐⭐⭐⭐
“My infertility journey was long and painful. Post treatment at Viezec, my uterus healed, and I delivered a healthy baby boy.”

Chloe S. – Sydney, Australia – October 2023 – ⭐⭐⭐⭐☆
“Stem cell therapy at Viezec gave me back the chance to be a mother. My ovarian function improved, and I conceived successfully.”

Layla H. – Istanbul, Turkey – May 2025 – ⭐⭐⭐⭐⭐
“Infertility had broken my confidence. After Viezec’s therapy, I achieved pregnancy, and I’m now enjoying motherhood after years of waiting.”

Female Infertility Happy Patient Videos

Female Infertility Stem Cell Treatment..Watch Video

Treatment Disclaimer

Is stem cell therapy a guaranteed cure for female infertility?

No. Stem cell therapy for female infertility is not a guaranteed cure, and no clinic — including Viezec — can promise pregnancy as an outcome. It is offered as a supportive, investigational option for specific causes of infertility, based on your individual diagnosis, and should not be understood as a replacement for established treatments like IVF where those are medically more appropriate.

What does the current evidence show?

Research into stem cell therapy for conditions like diminished ovarian reserve and thin endometrial lining is still evolving. Some published studies report improvements in ovarian markers or endometrial thickness in selected patients, while others show limited or inconsistent results. This is an active area of clinical research, not an established standard-of-care treatment recognized by major fertility bodies (such as ASRM or ESHRE) at this time.

Who is this treatment intended for?

Stem cell therapy at Viezec, New Delhi, India, is considered only after a full diagnostic work-up confirms a specific underlying cause — such as diminished ovarian reserve or thin endometrial lining — where existing evidence is more directly relevant. It is not offered as a first-line treatment, and it is not appropriate for every cause of infertility (for example, tubal blockage or structural abnormalities typically require different approaches).

What results can I realistically expect?

Individual results vary based on age, diagnosis, ovarian reserve, and overall health. We do not publish blanket improvement percentages, because outcomes differ significantly from patient to patient. During your consultation, our specialist will discuss what is realistic for your specific case based on your medical reports — not a generic success rate.

Who oversees treatment decisions?

All treatment plans are reviewed and overseen by our named treating specialist team based at our facility in New Delhi, India, following evaluation of your hormonal panel, ovarian reserve assessment, and uterine evaluation. No protocol is recommended without this evaluation.

Is this treatment regulated?

Stem cell therapies in India fall under specific regulatory frameworks depending on the cell type and application. We encourage every patient — whether considering treatment in India or elsewhere — to ask directly which regulatory framework applies and to verify the facility’s accreditation before proceeding.

Where can I get a specific answer for my case?

Because infertility has many possible causes, general information on this page cannot replace an individual medical evaluation. Book a consultation with our specialist team in New Delhi to review your reports and discuss whether you are a suitable candidate.